StockWireNews
Biopharma Monday: Low Float Nasdaq Profile (ENTO) Tops Today's Watchlist
March 3rd
Greetings Readers,
Reaching the top of my watchlist right now is Entero Therapeutics, Inc. (Nasdaq: ENTO).
Entero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted, non-systemic therapies for gastrointestinal (GI) diseases.
ENTO is developing a therapeutic pipeline rooted in a triad of exclusive technological breakthroughs:
Latiglutenase is a potentially first-in-class oral biotherapeutic designed to aid gluten digestion and reduce symptoms of celiac disease, currently in Phase 3-ready status.
Capeserod, a selective 5-HT4 receptor partial agonist, is being developed for multiple GI indications, including gastroparesis.
Adrulipase is a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in patients with exocrine pancreatic insufficiency, particularly those with cystic fibrosis and chronic pancreatitis.
The company is also developing niclosamide-based therapies for ulcerative proctitis and immune checkpoint inhibitor-associated colitis.
Read more about the company here.
-----
Entero Therapeutics, Inc. (Nasdaq: ENTO) is a low float breakout idea...
Right now, Yahoo Finance is reporting ENTO have approximately 4.69Mn shares in its float.
What does that mean? It means the volatility potential is elevated from there being so few shares available.
It could also be part of the reason why ENTO was able to climb 92% from a December 5th, 2024 open of $.48 to a December 9th high of $.926.
Now, there is no certainty another short term move like that will happen again, but it's key to take note that this Nasdaq profile's float size is fairly low.
-----
Coverage is officially initiated on Entero Therapeutics, Inc. (Nasdaq: ENTO).
When updates are available, I'll be in touch quickly. Talk again soon.
Sincerely,
Kai Parker
StockWireNews
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
ليست هناك تعليقات:
إرسال تعليق